Penghua Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Penghua Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Liang-Liang Wang
State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, People's Republic of China
2 shared publications Chen Zhang
School of Pharmacology Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China
1 shared publication- Guozhi Xiao
State Key Laboratory of Phytochemistry and Natural Medicines Kunming Institute of Botany Chinese Academy of Sciences University of Chinese Academy of Sciences Kunming 650201 China
1 shared publication - Haiqing He
State Key Laboratory of Phytochemistry and Plant Resources in West China Kunming Institute of Botany, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 132 Lanhei Road, Kunming 650201, China
1 shared publication Haiwei Shen
School of Pharmacology Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China
1 shared publicationJiale Peng
A School of Chemical Engineering , Sichuan University of Science and Engineering , Zigong , PR China
1 shared publication
Latest Publications
- 6 January 2025
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 12 (5) , 1572-1578
2-(1-Phenylvinyl)benzoic acid as a highly active leaving group for metal-free glycosylation
The efficient assembly of O -glycosides and N -glycosides has been achieved by activating glycosyl ortho -(1-phenylvinyl)benzoate (PVB) with I 2 .
- 6 January 2025
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 12 (5) , 1572-1578
2-(1-Phenylvinyl)benzoic acid as a highly active leaving group for metal-free glycosylation
The efficient assembly of O -glycosides and N -glycosides has been achieved by activating glycosyl ortho -(1-phenylvinyl)benzoate (PVB) with I 2 .
- Open Access
- 21 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-10
Glycosyl ortho-(1-phenylvinyl)benzoates versatile glycosyl donors for highly efficient synthesis of both O-glycosides and nucleosides
Both of O-glycosides and nucleosides are important biomolecules with crucial rules in numerous biological processes. Chemical synthesis is an efficient and scalable method to produce well-defined and pure carbohydrate-containing molecules for deciphering their functions and developing therapeutic agents. However, the development of glycosylation methods for efficient synthesis of both O-glycosides and nucleosides is one of the long-standing challenges in chemistry. Here, we report a highly efficient and versatile glycosylation method for efficient synthesis of both O-glycosides and nucleosides, which uses glycosyl ortho-(1-phenylvinyl)benzoates as donors. This glycosylation protocol enjoys the various features, including readily prepared and stable donors, cheap and readily available promoters, mild reaction conditions, good to excellent yields, and broad substrate scopes. In particular, the applications of the current glycosylation protocol are demonstrated by one-pot synthesis of several bioactive oligosaccharides and highly efficient synthesis of nucleosides drugs capecitabine, galocitabine and doxifluridine.
- 21 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-10
Open AccessGlycosyl ortho-(1-phenylvinyl)benzoates versatile glycosyl donors for highly efficient synthesis of both O-glycosides and nucleosides
Both of O-glycosides and nucleosides are important biomolecules with crucial rules in numerous biological processes. Chemical synthesis is an efficient and scalable method to produce well-defined and pure carbohydrate-containing molecules for deciphering their functions and developing therapeutic agents. However, the development of glycosylation methods for efficient synthesis of both O-glycosides and nucleosides is one of the long-standing challenges in chemistry. Here, we report a highly efficient and versatile glycosylation method for efficient synthesis of both O-glycosides and nucleosides, which uses glycosyl ortho-(1-phenylvinyl)benzoates as donors. This glycosylation protocol enjoys the various features, including readily prepared and stable donors, cheap and readily available promoters, mild reaction conditions, good to excellent yields, and broad substrate scopes. In particular, the applications of the current glycosylation protocol are demonstrated by one-pot synthesis of several bioactive oligosaccharides and highly efficient synthesis of nucleosides drugs capecitabine, galocitabine and doxifluridine.
- 14 November 2018
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 360 (24) , 4832-4836
Asymmetric Syntheses of Spirooxindole‐dihydroquinazolinones by Cyclization Reactions between N‐substituted Anthranilamides and Isatins
A variety of enantioenriched 3‐N‐substituted spirooxindole‐dihydroquinazolinones were synthesized by cyclization reactions involving 2‐amino‐N‐substituted benzamides and isatins catalyzed by SPINOL‐CPA catalyst in a highly enantioselective manner with excellent ee values (up to 99%) and good yields (up to 99%). So far, this is the first example to directly access this type of chiral pharmaceutically privileged 3‐N‐substituted dihydroquinazolinone derivatives with a broad substrate scope. magnified image
- 14 November 2018
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 360 (24) , 4832-4836
Asymmetric Syntheses of Spirooxindole‐dihydroquinazolinones by Cyclization Reactions between N‐substituted Anthranilamides and Isatins
A variety of enantioenriched 3‐N‐substituted spirooxindole‐dihydroquinazolinones were synthesized by cyclization reactions involving 2‐amino‐N‐substituted benzamides and isatins catalyzed by SPINOL‐CPA catalyst in a highly enantioselective manner with excellent ee values (up to 99%) and good yields (up to 99%). So far, this is the first example to directly access this type of chiral pharmaceutically privileged 3‐N‐substituted dihydroquinazolinone derivatives with a broad substrate scope. magnified image
- 4 May 2018
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 38 (3) , 213-224
Discovery of FIXa inhibitors by combination of pharmacophore modeling, molecular docking, and 3D-QSAR modeling
Human Coagulation Factor IXa (FIXa), specifically inhibited at the initiation stage of the blood coagulation cascade, is an excellent target for developing selective and safe anticoagulants. To explore this inhibitory mechanism, 86 FIXa inhibitors were selected to generate pharmacophore models and subsequently SAR models. Both best pharmacophore model and ROC curve were built through the Receptor–Ligand Pharmacophore Generation module. CoMFA model based on molecular docking and PLS factor analysis methods were developed. Model propagations values are q2 = 0.709, r2 = 0.949, and r2pred = 0.905. The satisfactory q2 value of 0.609, r2 value of 0.962, and r2pred value of 0.819 for CoMSIA indicated that the CoMFA and CoMSIA models are both available to predict the inhibitory activity on FIXa. On the basis of pharmacophore modeling, molecular docking, and 3D-QSAR modeling screening, six molecules are screened as potential FIXa inhibitors.
- 4 May 2018
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 38 (3) , 213-224
Discovery of FIXa inhibitors by combination of pharmacophore modeling, molecular docking, and 3D-QSAR modeling
Human Coagulation Factor IXa (FIXa), specifically inhibited at the initiation stage of the blood coagulation cascade, is an excellent target for developing selective and safe anticoagulants. To explore this inhibitory mechanism, 86 FIXa inhibitors were selected to generate pharmacophore models and subsequently SAR models. Both best pharmacophore model and ROC curve were built through the Receptor–Ligand Pharmacophore Generation module. CoMFA model based on molecular docking and PLS factor analysis methods were developed. Model propagations values are q2 = 0.709, r2 = 0.949, and r2pred = 0.905. The satisfactory q2 value of 0.609, r2 value of 0.962, and r2pred value of 0.819 for CoMSIA indicated that the CoMFA and CoMSIA models are both available to predict the inhibitory activity on FIXa. On the basis of pharmacophore modeling, molecular docking, and 3D-QSAR modeling screening, six molecules are screened as potential FIXa inhibitors.